Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
RESEARCH TOOLSreports
Karyopharm Therapeutics (KPTI) Stock Price & Analysis
1,072 Followers
KPTI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.62 - $2.67
Previous Close$1.15
Volume1.56M
Average Volume (3M)1.31M
Market Cap
$135.37M
Enterprise Value$120.94M
Total Cash (Recent Filing)$191.44M
Total Debt (Recent Filing)$177.02M
Price to Earnings (P/E)-0.9
Beta1.66
Next Earnings
Aug 01, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding117,710,263
10 Day Avg. Volume1,501,596
30 Day Avg. Volume1,312,976
Standard Deviation0.21
R-Squared0.00151
Alpha-0.00481
Financial Highlights & Ratios
Price to Book (P/B)-0.98
Price to Sales (P/S)0.93
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit0.86
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$5.17Price Target Upside349.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Karyopharm Therapeutics News
PremiumCompany Announcements
Karyopharm Therapeutics Enhances Financial Stability and Liquidity
PremiumPre-Earnings
Is KPTI a Buy, Before Earnings?
PremiumCompany Announcements
Bad News for Karyopharm Therapeutics INC Stock: This New Risk Has Been Added
Bulls Say, Bears Say
Bulls Say
Financial StabilitySignificant debt restructuring, delaying majority of repayments until 2028/2029.
Regulatory MilestonesFull marketing approval authorization from the UK's MHRA for Nexpovio in combination with Velcade and dexamethasone.
Research And DevelopmentEncouraging early Phase 3 data for endometrial maintenance and compelling market opportunities.
Bears Say
Financial PerformanceKaryopharm reported 4Q23 revenue and EPS below estimates, indicating a less favorable financial performance.
Market CompetitionIncreasing competition and higher discounts and rebates have adversely impacted Xpovio sales, hinting at market challenges for the product.
Sales GuidanceXpovio 2024 guidance provided for the first time is below expectations.
---
Ownership Overview
15.61% Insiders
13.54% Mutual Funds
37.32% Other Institutional Investors
33.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $0.62 and its highest was $2.67 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Currently, no data Available
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on May 08, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.334 by $0.014.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -$0.31.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 117,710,266 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.334. Following the earnings report the stock price went down -7.273%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Among the largest hedge funds holding Karyopharm Therapeutics’s share is Woodline Partners LP. It holds Karyopharm Therapeutics’s shares valued at 203K.
---
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.17 (349.57% Upside)
$5.17 (349.57% Upside)
Blogger Sentiment
Bullish
KPTI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 9.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.24%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
---
KPTI Company Deck
---
KPTI Earnings Call
Q1 2024
0:00 / 0:00
---
KPTI Stock 12 Month Forecast
Average Price Target
$5.17
▲(349.57% Upside)
Technical Analysis
Best Analysts Covering KPTI
1 Year
1 Year Success Rate
4/26 ratings generated profit
1 Year Average Return
-38.21%
reiterated a buy rating 10 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -38.21% per trade.
---